3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
12
Multiple Myeloma
9
Lymphoma
8
Breast Neoplasms
8
Lymphoma, Non-Hodgkin
7
Hodgkin Disease
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Neuroblastoma
6
Lymphoma, Large B-Cell, Diffuse
4
Central Nervous System Neoplasms
4
Burkitt Lymphoma
4
Sarcoma
3
Medulloblastoma
3
Leukemia
3
Brain Neoplasms
3
Anemia, Refractory, with Excess of Blasts
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Retinoblastoma
2
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Malignant mesenchymal tumor
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Follicular
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Interventions
pegylated granulocyte colony-stimulating factor, human
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Chemotherapy Induced Neutropenia
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT01674855
2014-10-01
PEG-G-CSF
Dong-A ST Co., Ltd.
Phase 3
Completed
74 enrolled